yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
Patient Home Monitoring (PHM) Announces a Profitable First Quarter of Fiscal 2013 with Strong Cash Flow; and Audited Fiscal Year 2012 Results

SAN FRANCISCO, CALIFORNIA -- (Marketwire) -- 01/29/13 -- Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a company focused on in-home cardiology healthcare services, today announced audited results for its fiscal year ended September 30, 2012. It also released unaudited results for its first quarter of fiscal 2013 ended December 31, 2012. In conjunction with the results, PHM's management provided details behind the impressive triple digit revenue growth in fiscal 2012 as well as strong first quarter cash flow and profitability.

PHM will broadcast an earnings call and webcast on Tuesday, January 29, 2013 at 12:00 pm ET to review and discuss the first fiscal quarter of 2013 and the fiscal year end results for 2012.

To listen, please visit PHM's investor website at:

Q1 2013 Highlights

Quarterly Net Profit

--  Swung to a net profit of $96,449 from a loss of $65,229 in the previous
    quarter. An increase in profit of $161,678 for the quarter. 

Quarterly Cash Flow

--  Generated positive cash flow of $199,853, an increase of $410,028 in
    cash flow compared to the previous quarter. 

PHM's Adjusted EBITDA(1) (Operating Profit) Trend from Q1 FY 2012 to Q1 FY 2013

Adjusted EBITDA (EBITDA excluding options expenses)                         
       Q1 FY 12        Q2 FY 12        Q3 FY 12       Q4 FY 12      Q1 FY 13
       ($74,767)      ($113,726)        $28,489        $53,001      $254,943

"The results for the first quarter of fiscal 2013 highlight our increasing profitability and cash flow." said Dr. Jaime Gerber MD, CEO of PHM. "In FY 2012, we accelerated profit growth and with this most recent quarter, we are pleased to have generated our first full quarter of profit. The strong cash flow from this quarter reaffirms the increasing value of PHM to its shareholders."

"We are happy to announce that in FY 2012, we increased top line revenue by 170% despite an 11% reimbursement cut," continued Dr. Gerber, "PHM operates in an underpenetrated market that remains poised for growth, with over 3.5 million patients available for enrollment. Our focus on service quality and fiscal efficiency creates value for our patients, physicians, and shareholders. We have reached a critical mass in our annuity stream revenue where each additional patient drives significant annual cash flow and profitability."

Full Year Audited 2012 Highlights


--  Increased annual revenue to $3,901,058 from $1,443,708, a 170% increase
    over the prior year. 


--  Generated $990,312 in Adjusted EBITDA before patient acquisition
    costs(1) (operating profit), a swing of $1,420,990 from fiscal 2011. 
--  Narrowed Adjusted EBITDA losses to $107,004 in 2012 from $1,378,312 in
--  Increased quarterly gross profit margin to 67.3% from 59.5% in FY 2011
    in the face of an 11% reimbursement cut. 

For complete financial results, please see PHM's filings at

(1) Operational Profitability is defined as Adjusted EBITDA before patient acquisition costs. In calculating Adjusted EBITDA before patient acquisition costs certain items are excluded from net loss including interest, taxes, amortization, non-cash stock-based compensation, and patient acquisition costs. Please refer to the "Non-IFRS Measures" section of PHM's MD&A for further discussion on these operational measures at:

                         Q1 FY 12      Q2 FY 12      Q3 FY 12      Q4 FY 12 
Net Gain (Loss)       $  (165,384)  $  (193,268)  $  (115,882)  $   (65,229)
Add Back: Interest                                                          
 Expense              $     1,619   $    25,332   $    27,406   $    15,818 
Add Back:                                                                   
 Amortization         $    59,233   $    67,712   $    79,219   $    86,984 
Add Back: Stock                                                             
 Based Comp.          $    29,764   $   (13,502)  $    37,746   $    15,428 
Adjusted EBITDA       $   (74,768)  $  (113,726)  $    28,489   $    53,001 
Add Back: Patient                                                           
 Acquisition Costs    $   293,133   $   269,351   $   254,553   $  280, 279 
Adjusted EBITDA                                                             
 before Pat. Acq.     $   218,365   $   155,625   $   283,042   $   333,280 

                              Q1 FY 13           FY 2011            FY 2012 
Net Gain (Loss)        $        96,449   $    (1,641,001)   $      (539,763)
Add Back: Interest                                                          
 Expense               $        28,060   $             -    $        70,175 
Add Back:                                                                   
 Amortization          $        86,763   $       121,221    $       293,148 
Add Back: Stock                                                             
 Based Comp.           $        43,671   $       141,468    $        69,436 
Adjusted EBITDA        $       254,943   $    (1,378,312)   $      (107,004)
Add Back: Patient                                                           
 Acquisition Costs     $       144,073   $       947,634    $     1,097,316 
Adjusted EBITDA                                                             
 before Pat. Acq.      $       399,016   $      (430,678)   $       990,312 

About PHM

PHM is a healthcare services company focused on providing in-home testing for patients on blood thinner medications such as Coumadin® or warfarin. Medicare recently expanded reimbursement for in-home patient self testing (PST) of blood coagulation levels. PHM has a unique value proposition to cardiology groups that manage patients on blood thinners, focusing on systemization to enroll patients in PST. This unique, systemized approach creates an opportunity for physician groups to operate more efficiently, increasing revenue to their clinic while providing a higher standard of care for patients.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Patient Home Monitoring
Michael Dalsin
Managing Director, Stanmore Capital Partners, Inc
(323) 253-3055

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

SOA World Latest Stories
Saviynt Inc. has announced the availability of the next release of Saviynt for AWS. The comprehensive security and compliance solution provides a Command-and-Control center to gain visibility into risks in AWS, enforce real-time protection of critical workloads as well as data and auto...
In a report titled “Forecast Analysis: Enterprise Application Software, Worldwide, 2Q15 Update,” Gartner analysts highlighted the increasing trend of application modernization among enterprises. According to a recent survey, 45% of respondents stated that modernization of i...
Docker is hot. However, as Docker container use spreads into more mature production pipelines, there can be issues about control of Docker images to ensure they are production-ready. Is a promotion-based model appropriate to control and track the flow of Docker images from development ...
As the world moves towards more DevOps and microservices, application deployment to the cloud ought to become a lot simpler. The microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a...
In their session at DevOps Summit, Asaf Yigal, co-founder and the VP of Product at, and Tomer Levy, co-founder and CEO of, will explore the entire process that they have undergone – through research, benchmarking, implementation, optimization, and customer success – in ...
DevOps has often been described in terms of CAMS: Culture, Automation, Measuring, Sharing. While we’ve seen a lot of focus on the “A” and even on the “M”, there are very few examples of why the “C" is equally important in the DevOps equation. In her session at @DevOps Summit, Lori MacV...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers